<DOC>
	<DOCNO>NCT02715479</DOCNO>
	<brief_summary>The purpose study evaluate BMS955176 affect pharmacokinetics ( PK ) Dolutegravir ( DTG ) also DTG administration affect PK BMS955176</brief_summary>
	<brief_title>A Study Evaluate Effect BMS-955176 Pharmacokinetics Dolutegravir Effect Dolutegravir Pharmacokinetics BMS-955176</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>1 . Signed Informed Consent 2 . Target population : Healthy male female . 3 . Women child bear potential ( WOCBP ) negative serum pregnancy test 4 . Women must breastfeed 5 . Men WOCBP must agree follow instruction contraception 1 . History chronic acute illness , gastrointestinal disease , GI surgery , cardiac disease clinically significant cardiac arrhythmia 2 . History frequent headache acute diarrhoea . 3 . Any major surgery within 4 week study drug administration 4 . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination beyond consistent target population 5 . History allergy HIV maturation integrase inhibitor , related compound 6 . History smoking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>